- Home
- MRVI
as of 12-15-2025 11:15am EST
$3.66
+$0.05
+1.25%
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Chart Type:
Time Range:
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 449.6M | IPO Year: | 2020 |
| Target Price: | $4.58 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.67 - $6.21 | Next Earning Date: | 11-06-2025 |
| Revenue: | $192,435,000 | Revenue Growth: | -30.47% |
| Revenue Growth (this year): | -27.01% | Revenue Growth (next year): | 9.04% |
AI-Powered MRVI Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 67.32%
67.32%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Maravai LifeSciences Holdings Inc. (MRVI)
LUCIER GREGORY T
Buy
Director
MRVI Dec 8, 2025
Avg Cost/Share
$3.67
Shares
48,528
Total Value
$178,097.76
Owned After
155,123
SEC Form 4
LUCIER GREGORY T
Buy
Director
MRVI Dec 5, 2025
Avg Cost/Share
$3.70
Shares
51,472
Total Value
$190,446.40
Owned After
155,123
SEC Form 4
Brust Bernd
Buy
Chief Executive Officer
MRVI Nov 13, 2025
Avg Cost/Share
$3.25
Shares
216,212
Total Value
$702,689.00
Owned After
466,771
SEC Form 4
Brust Bernd
Buy
Chief Executive Officer
MRVI Nov 12, 2025
Avg Cost/Share
$3.21
Shares
93,358
Total Value
$299,679.18
Owned After
466,771
SEC Form 4
Brust Bernd
Buy
Chief Executive Officer
MRVI Nov 11, 2025
Avg Cost/Share
$3.24
Shares
157,201
Total Value
$509,331.24
Owned After
466,771
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| LUCIER GREGORY T | MRVI | Director | Dec 8, 2025 | Buy | $3.67 | 48,528 | $178,097.76 | 155,123 | |
| LUCIER GREGORY T | MRVI | Director | Dec 5, 2025 | Buy | $3.70 | 51,472 | $190,446.40 | 155,123 | |
| Brust Bernd | MRVI | Chief Executive Officer | Nov 13, 2025 | Buy | $3.25 | 216,212 | $702,689.00 | 466,771 | |
| Brust Bernd | MRVI | Chief Executive Officer | Nov 12, 2025 | Buy | $3.21 | 93,358 | $299,679.18 | 466,771 | |
| Brust Bernd | MRVI | Chief Executive Officer | Nov 11, 2025 | Buy | $3.24 | 157,201 | $509,331.24 | 466,771 |
Latest Maravai LifeSciences Holdings Inc. News
MRVI Breaking Stock News: Dive into MRVI Ticker-Specific Updates for Smart Investing
Compare MRVI vs Leading Stocks
See how MRVI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MRVI Maravai LifeSciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.